Detalles de la búsqueda
1.
In-solution buffer-free digestion allows full-sequence coverage and complete characterization of post-translational modifications of the receptor-binding domain of SARS-CoV-2 in a single ESI-MS spectrum.
Anal Bioanal Chem
; 413(30): 7559-7585, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34739558
2.
Real-world effectiveness of the heterologous SOBERANA-02 and SOBERANA-Plus vaccine scheme in 2-11 years-old children during the SARS-CoV-2 Omicron wave in Cuba: a longitudinal case-population study.
Lancet Reg Health Am
; 34: 100750, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38699214
3.
Comparative Immune Response after Vaccination with SOBERANA® 02 and SOBERANA® plus Heterologous Scheme and Natural Infection in Young Children.
Vaccines (Basel)
; 11(11)2023 Oct 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38005968
4.
Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial.
Lancet Reg Health Am
; 18: 100423, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36618081
5.
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children.
Int J Infect Dis
; 126: 164-173, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36403819
6.
A randomized, double-blind phase I clinical trial of two recombinant dimeric RBD COVID-19 vaccine candidates: Safety, reactogenicity and immunogenicity.
Vaccine
; 40(13): 2068-2075, 2022 03 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35164986
7.
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial.
Lancet Respir Med
; 10(8): 785-795, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35691295
8.
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults.
Med
; 3(11): 760-773.e5, 2022 11 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35998623
9.
A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles.
RSC Chem Biol
; 3(2): 242-249, 2022 Feb 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35360883
10.
Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials.
Vaccine
; 40(31): 4220-4230, 2022 07 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-35691871
11.
Glycan Array Evaluation of Synthetic Epitopes between the Capsular Polysaccharides from Streptococcus pneumoniae 19F and 19A.
ACS Chem Biol
; 16(9): 1671-1679, 2021 09 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-34469105
12.
Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines.
ACS Cent Sci
; 7(5): 757-767, 2021 May 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34075345
13.
SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies.
ACS Chem Biol
; 16(7): 1223-1233, 2021 07 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-34219448
14.
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial.
Lancet Reg Health Am
; 4: 100079, 2021 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-34541571
15.
Synthetic, Zwitterionic Sp1 Oligosaccharides Adopt a Helical Structure Crucial for Antibody Interaction.
ACS Cent Sci
; 5(8): 1407-1416, 2019 Aug 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-31482123
16.
Design and Biological Assembly of Polyester Beads Displaying Pneumococcal Antigens as Particulate Vaccine.
ACS Biomater Sci Eng
; 4(9): 3413-3424, 2018 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33435075
17.
Safety and immunogenicity of the Cuban heptavalent pneumococcal conjugate vaccine in healthy infants. Results from a double-blind randomized control trial Phase I.
Vaccine
; 36(32 Pt B): 4944-4951, 2018 08 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30005948
18.
From individual to herd protection with pneumococcal vaccines: the contribution of the Cuban pneumococcal conjugate vaccine implementation strategy.
Int J Infect Dis
; 60: 98-102, 2017 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28457742
19.
Corrigendum to "Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein" [Vaccine 40(20) (2022) 2856-2868].
Vaccine
; 40(48): 7009, 2022 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36374711
20.
Prevalence of Pneumococcal Nasopharyngeal Carriage Among Children 2-18 Months of Age: Baseline Study Pre Introduction of Pneumococcal Vaccination in Cuba.
Pediatr Infect Dis J
; 36(1): e22-e28, 2017 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27649366